-
Most Recent
APOP
Short Squeeze Stocks: BMRA, PROG and 3 Other Stocks Experts Think Are Ready to Pop
According to Fintel, these five short squeeze stocks are among the most likely to see a squeeze attempt moving forward. Let's take a look.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investor! We're jumping back into the stock market as we take a look at the biggest pre-market stock movers for Wednesday.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's been a long holiday weekend but we're getting right back into the swing of things with a look at the pre-market stock movers for today!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're kicking off a new week of trading with a look at the biggest pre-market stock movers for Monday and that includes winners and losers.
Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop
Short squeeze stocks have been targeted quite a bit lately as retail traders tackle them in an effort to push out hedge funds.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading for the week and we're kicking it off right with a look at the pre-market stock movers for Friday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers for Thursday and it includes loads of medical stocks.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're kicking off another exciting week of trading with a look at the biggest pre-market stock movers for Monday morning.
Market Update: The 10 Most Volatile Stocks Today
Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day.
APOP Stock: Why Cellect Biotechnology Is Skyrocketing Today
APOP stock holders are getting a 1:3 ratio of shares in the tie-up deal. The merger brings together Cellect's stem cell tech with Quoin's rare and orphan diseases focus.
Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday Morning
Pre-market movers this morning include some high-profile top gainers and losers. Take a look at this list that includes NFT stocks and EV plays.
Cellect Biotechnology News: APOP Stock Rockets 76% on New Patent Approvals
Cellect Biotechnology (APOP) news for Tuesday includes new patent approvals overseas that have APOP stock soaring higher.
High-Level Quant Score Keep Cellect Biotechnology (APOP) a Buy
With a $42.0 billion market value, Cellect Biotechnology Ltd (NULL:APOP) ranks in the top decile in its industry group, Biotechnology, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's Portfolio Grader ranking places it 46 among the 350 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 116 among the 782 companies in the sector, and number 670 in the nearly 5,000 company Portfolio Grader universe.
Robust Quant Score Make Cellect Biotechnology (APOP) a Buy
Cellect Biotechnology Ltd (NULL:APOP) is ranked as a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. The current Portfolio Grader recommendation on the shares has been in place for 4 months.
Quant Score Make Cellect Biotechnology (APOP) a Buy
Cellect Biotechnology Ltd (NULL:APOP) is ranked as a Buy using Louis Navellier's investing system and his Portfolio Grader stock evaluator. APOP has maintained this ranking for 4 months.
Cellect Biotechnology (APOP) a Buy on Robust Quant Score
The current recommendation of Buy for Cellect Biotechnology Ltd (NULL:APOP) is the result of using Louis Navellier's investing approach and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 4 months.
Solid Quant Score Make Cellect Biotechnology (APOP) a Buy
With a $44.3 billion market value, Cellect Biotechnology Ltd (NULL:APOP) ranks in the top 10% of its industry group, Biotechnology, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, the stock's Portfolio Grader ranking places it 37 among the 349 companies in this industry group, placing it among the leaders; in the top quartile of the sector with a ranking of 107 among the 782 companies in the sector, and number 707 in the nearly 5,000 company Portfolio Grader universe.
Cellect Biotechnology (APOP) a Buy on High-Level Quant Score
Cellect Biotechnology Ltd (NULL:APOP) is ranked as a Buy using Louis Navellier's system for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 4 months.
